Sai Parenterals Limited Plans for IPO, Files DRHP With SEBI
Pharmaceutical company, Sai Parenterals Limited is planning for its Initial Public Offering (IPO) and has filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company is engaged in the manufacturing and marketing of a wide range of intravenous (IV) fluids, injections, and other healthcare formulations.
Sai Parenterals Limted IPO Details
According to the DRHP,
- Sai Parenterals will be a bookbuilding IPO, consisting of a fresh issue of ₹285 crore and an offer for sale (OFS) of 35 lakh equity shares, each with a face value of ₹5.
- The equity shares are proposed to be listed on the National Stock Exchange (NSE) and BSE, as per the DRHP.
- Arihant Capital Markets Limited will be the book-running lead managers of the public issue.
- Bigshare Services Private Limited will be the registrar for the Sai Parenterals IPO.
Utilisation of Proceeds
The Company proposes to utilise the Net Proceeds from the fresh issue for the following purposes:
- Capacity expansion and upgradation of manufacturing facilities.
- Establishment of a new R&D Centre.
- Repayment / prepayment of certain outstanding borrowings.
- Working capital requirements.
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
- General corporate purposes.
Check out newly Listed IPOs on BSE and NSE.
About Sai Parenterals Limited
Sai Parenterals Ltd, founded in 2001 and headquartered in Hyderabad, is engaged in the development and manufacturing of sterile pharmaceutical formulations. The company specializes in parenteral products, including injectables (liquid and dry powder), oral solids and liquids, and topical preparations. It operates multiple WHO-GMP-approved manufacturing facilities across India and also provides contract development and manufacturing (CDMO) services to domestic and global clients.
Financially, in FY 2022 the company reported a turnover of around ₹100 crore, reflecting its growing presence in the injectables and CDMO segment. In 2025, it raised ₹50 crore in equity funding from investors such as Samarsh Capital and Vyom Partners to expand its global footprint and enhance production capacity.
Explore other Upcoming IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.